ERBB2 and aneurysmal bone cyst: The NALA randomized phase III trial was recently completed to evaluate the efficacy of the combination neratinib-capecitabine at the above-mentioned dose, compared with lapatinib-capecitabine in patients with heavily pretreated HER2-positive ABC (NCT01808573).